8th Edition Updates

​​
 

 AJCC Annual Meeting 2014 General Session Broadcast

 

September 23rd, 2014 

8th Edition Updates from Editor-in-Chief Dr. Mahul B. Amin
 
Below is the full AJCC Annual Meeting 2014 General Session broadcasted from Chicago headquarters on September 12, 2014. 

Key Time Marks 

2:25 - Welcome New Members
4:32 - Welcome Guests
6:14 - Staff Updates
8:00 - Thank You for your Service!
9:30 - AJCC Year in Review
36:35 - 8th Edition Update – Mahul B. Amin, MD, FCAP, Cedars-Sinai Medical Center, Los Angeles, CA
1:21 - Standing Committee Chair Updates
1:31 - Audience Interactive Session for Chicago audience
2:05 - Keynote Address -“Connecting Patients, Providers, and Payers” – John D. Halamka, MD, MS, Chief Information Officer, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, MA

At time mark 36:35, the 8th Edition Editor-In-Chief Dr. Mahul B. Amin took the podium and spoke on the 8th Edition progress and updates, “The Bridge from a Population Based to a More Personalized Approach.” Dr. Amin started his presentation with an overview of the vision, structure and implementation for 8th Edition along with a brief historical perspective of the AJCC and more importantly the Staging manual. The first edition was published in 1977 and Dr. Amin went through the subsequent staging manuals that followed. Amin spoke to the persistent challenges to TNM Staging: TNM does not meet needs of clinicians and patients, TNM largely limited to anatomic information and TNM must maintain anatomic base.

He then went into an overview of what has changed since the 7th edition including advances in molecular underpinnings of cancer, increased availability of high throughput testing, advances in informatics & computational biology, increased coordination in cancer care, maturing data, oncology therapies becoming more sophisticated and the globalization of cancer.

The vision for the 8th Edition will provide the definitive, comprehensive, proactive, evidence-based, contemporary, clinically relevant taxonomy of human neoplasia.

Through the past months, summer 2014, the editorial board has developed: Standardized chapter outline – will serve as a template for most chapters (except for non-TNM sites - CNS, lymphoma & leukemia) along with General staging rules to be used consistently in all chapters - proposed by Content Harmonization Core will be finalized by editorial board by Jan 1, 2015.

Dr. Amin closed with stating that the 8th Edition strategic and operational plans are ambitious but set in accordance with “high expectations” of the next upgrade of the AJCC system which has become synonymous with cancer prognostication, management, research and reporting

The work performed in past 18 months is nothing short of monumental and exemplifies team work at its best – thanks to the Executive Committee, the 8th Edition Editorial Board members & AJCC leadership and staff at the Chicago office.

For a full overview and agenda of the General Session For a full overview and agenda of the General Session For a full overview and agenda of the General Session click here​.

 

 8th Edition Expert Panel Orientation

 


April 23rd, 2014


On Thursday, April 3rd, the Editorial Board, Expert Panel Chairs and Vice Chairs for the AJCC Cancer Staging System met in Chicago to discuss plans for the 8th Edition. Editor-in-Chief Mahul B. Amin, MD, FCAP presented his vision for the project to the group, which focuses on integration of molecular biomarkers for more accurate disease stratification and inclusion of all cancer specialties in the authoring process.

Chief among the orientation presentations was the Cancer Staging Content Transformation Project (CSCoT) - a content harmonization initiative by the AJCC to further enhance usability of the staging system by providing clearer staging rules and references for the 8th Edition and all future editions. The afternoon session focused on the Editorial Board Cores that will provide support for content harmonization, levels of evidence, integration of precision medicine, and data collection. The group capped off the day with a breakout session focusing on how AJCC can integrate personalized medicine into the TNM staging system. 

For continued 8th Edition news be sure to follow us on Twitter for live updates. ​

 

 Introducing the AJCC 8th Edition Editorial Board and Expert Panel Leaders

 

February 20th, 2014
 
The AJCC is pleased to introduce the thought leaders of the AJCC Cancer Staging System, 8th Edition.
 

Led by Mahul B. Amin, MD, FCAP, the 15 member Editorial Board features representatives from each cancer specialty, and leaders of internal development “cores” – a new concept introduced by Dr. Amin.  These cores are tasked with harmonizing specific areas of staging system development, including:
 
  • Precision Medicine Core – focused on integrating non-anatomic prognostic factors into the staging system
  • Evidence Based Medicine and Statistics Core – focused on developing levels of evidence for changes and updates to the staging system
  • Content Harmonization Core – focused on harmonizing terms and concepts used in the staging system
  • Data Collection Core – focused on collaboration with the surveillance community to assure medical record access to and quality of 8th edition data elements
  • Professional Organization and Corporate Relationship Core – manages grants and contributions for development of the AJCC Cancer Staging System
  • Administrative Core – oversees the development process of the staging system
 
The 8th Edition will be authored by a team of 18 Expert Panels, each steered by a Chair and Vice Chair selected by the Editorial Board.  The composition of each expert panel strives to collaboratively harness the collective intelligence of the thought leaders for each disease site.  The membership represents diversity of thought and specialty; each panel's Chair and Vice Chair come from different organizations and represent different specialties.   
 
 
The full roster of Editorial Board members and Expert Panel leaders can be found here.
 
 
Formation of the full expert panels is underway and is expected to be completed by year-end.  
 
 
The 8th edition will be effective for all cancer cases recorded on or after January 1, 2017.  Visit our website for all 8th Edition Updates.  We look forward to a collaborative development process!
 
 

 8th Edition Publication Date Announced

 
 
November 20th, 2013
 

The AJCC Executive Committee recently announced a mid-2016 publication date for the 8th edition AJCC Cancer Staging System during its 2013 Annual Meeting held this September in Chicago.  The 8th edition will be effective for all cancer cases recorded on or after January 1, 2017.  Key activities prior to the 2016 publication date include: 

  • careful analysis of data collected since the 7th Edition's release in 2010;
  • thoughtful validation of prognostic and predictive factors for incorporation in the staging system; and
  • continued deep collaboration with standard setters and key partners to anticipate, communicate, and help incorporate staging system changes to the cancer care and surveillance community.

Keep checking here for more 8th Edition updates.  We look forward to an exciting development process! ​

 

 Editor-in-Chief Announced for AJCC Cancer Staging Manual, 8th Edition

 

August 6th, 2013

 
Dr. Amin brings multidisciplinary approach and molecular-based medical perspective on cancer staging to national editorial positionAmin Mahul - Path.jpg

Mahul B. Amin, MD, FCAP, has been named Editor-in-Chief of the upcoming eighth edition of the AJCC Cancer Staging Manual. Dr. Amin is currently Chairman and Professor of the Department of Pathology and Laboratory Medicine at Cedars-Sinai Medical Center, Los Angeles.  
 
The eighth edition of the Cancer Staging Manual, which is expected to be published in late 2016 for patients diagnosed with cancer after January 2017, will incorporate advances made in cancer research, staging, diagnosis, and treatment since the seventh edition was published in October 2009.
 
The editorial development process will involve a collaboration of approximately 500 cancer experts from around the world, and will cover more than 60 primary disease sites.